Education
About Us
Working with TipRanks
Follow Us
908 Devices Inc. (MASS)
NASDAQ:MASS
Top Page
908 Devices
(NASDAQ:MASS)
Select Model
Select Model
Rating:58Neutral
Price Target:
$6.50
▲(4.84% Upside)
Action:ReiteratedDate:03/09/26
The score is held back primarily by weak profitability and negative TTM operating/free cash flow, partially offset by a strong, low-leverage balance sheet. The latest earnings call adds support via solid 2026 growth/margin guidance and improving operational traction, while technicals remain mixed and valuation appears relatively inexpensive on P/E but lacks dividend support.
Positive Factors
Balance sheet strength
A strong cash position and low leverage provide durable financial flexibility to fund R&D, absorb cyclical revenue shortfalls, and execute go-to-market expansion without immediate refinancing. This materially reduces solvency risk and supports multi-quarter investment pacing.
Recurring revenue mix
A consumables, service and software base representing ~35% of revenue and growing at 22% creates a recurring revenue backbone that smooths sales volatility, increases lifetime customer value, and supports margin durability as installed base scales.
Margin expansion & 2026 guidance
Management’s guidance signals sustained gross margin expansion and a clear plan to materially cut adjusted EBITDA losses. If executed, higher product margins and controlled OpEx improve the structural path to profitability and free cash flow conversion over multiple quarters.
Negative Factors
Negative operating cash flow
Persistent negative operating and free cash flow indicate ongoing cash burn despite reported net income improvements. Continued negative cash conversion could force financing, restrict reinvestment, or require slower expansion if internal cash generation does not improve within several quarters.
Annual EBITDA still loss-making
Although Q4 showed adjusted EBITDA positivity, the full-year adjusted EBITDA loss underscores that profitability is not yet durable. Annual losses imply continued dependence on cash reserves and that operational turnarounds must persist across multiple quarters to prove stability.
Concentration on lumpy government programs
Reliance on federal contracts and grant timing creates structural revenue volatility and forecasting difficulty. Program awards and DHS appropriations uncertainty can produce lumpy receipts and planning risk, weakening the predictability of top-line growth and resource allocation over quarters.
908 Devices (MASS) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$232.50M
Dividend YieldN/A
Average Volume (3M)287.60K
Price to Earnings (P/E)9.8
Beta (1Y)0.99
Revenue Growth4.49%
EPS Growth3.61%
CountryUS
Employees246
SectorHealthcare
Sector Strength45
IndustryMedical - Devices
Share Statistics
EPS (TTM)0.01
Shares Outstanding37,379,950
10 Day Avg. Volume334,678
30 Day Avg. Volume287,599
Financial Highlights & Ratios
PEG Ratio-0.08
Price to Book (P/B)1.32
Price to Sales (P/S)3.38
P/FCF Ratio-7.72
Enterprise Value/Market Cap0.50
Enterprise Value/Revenue2.08
Enterprise Value/Gross Profit4.11
Enterprise Value/Ebitda-5.43
Forecast
1Y Price Target
$7.16Price Target Upside15.48% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering3
EPS Forecast (FY)-0.32
Revenue Forecast (FY)$65.33M
908 Devices Business Overview & Revenue Model
Company Description908 Devices Inc., a commercial-stage technology company, provides various purpose-built handheld and desktop mass spectrometry (Mass Spec) devices to interrogate unknown and invisible materials in life sciences research, bioprocessing, industrial biotech, forensics, and adjacent markets. The company's products include MX908, a handheld, battery-powered, and Mass Spec device that is designed for rapid analysis of gas, liquid, and solid materials of unknown identity; Rebel, a small desktop analyzer that provides real-time information on the extracellular environment in bioprocesses; and ZipChip solution, a plug-and-play, high-resolution separation platform that optimizes Mass Spec sample analysis. It operates in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. The company was incorporated in 2012 and is headquartered in Boston, Massachusetts.
How the Company Makes Money908 Devices generates revenue primarily through the sale of its analytical devices and associated software solutions. The company's key revenue streams include direct sales of hardware, ongoing service contracts, and software licenses. Additionally, 908 Devices benefits from partnerships with key players in the pharmaceutical and safety sectors, which can lead to collaborative projects and bulk purchasing agreements. The company may also explore opportunities in government contracts and grants, particularly within defense and public safety applications, contributing to its overall earnings.
908 Devices Earnings Call Summary
Earnings Call Date:Mar 03, 2026
(Q4-2025)
| % Change Since: |
Next Earnings Date:May 12, 2026
Earnings Call Sentiment Positive
The call emphasized clear operational progress: accelerating product adoption (Explorer, Viper), meaningful revenue growth (Q4 +21%, FY +18%), improved margins, a positive Q4 adjusted EBITDA, and a strong cash position ($113M). At the same time, material non‑cash charges influenced full-year reported losses, adjusted EBITDA remains negative for the year, some production and contracting timing risks persist, and planned investments could moderate near‑term margin improvement. Management provided constructive 2026 guidance (15%–20% revenue growth; margin expansion; halving adjusted EBITDA loss), signaling confidence in execution while acknowledging remaining risks.Q4-2025 Updates
Positive Updates
Quarterly Revenue Growth
Q4 2025 revenue from continuing operations was $17.4M, up 21% year-over-year from $14.3M, driven by demand for Explorer, initial Viper shipments, and U.S. state & local adoption.
Full-Year Revenue and CAGR
Full-year 2025 revenue was $56.2M, an 18% increase versus $47.7M in 2024, in line with the company's five-year CAGR performance and driven by FTIR products (Viper) and Explorer.
Adjusted EBITDA Turnaround in Quarter
Adjusted EBITDA was positive $0.7M in Q4 2025 versus a loss of $4.0M in the prior-year quarter — a $4.7M improvement that the company attributes to cost and structural initiatives.
Profitability and Margin Improvements
Q4 gross profit was $9.2M (gross margin 53% vs 47% prior year); adjusted gross margin was 57%, up ~530 basis points year-over-year for the quarter. Full-year adjusted gross margin was 57% (vs 56% prior year).
Strong Product Momentum — Explorer & Viper
Explorer (first full year commercial) shipped over 150 units and grew >40% year-over-year; Viper (launched July 2025) shipped >40 units in Q4 and generated >$3M in Q4 revenue, indicating strong early adoption.
Recurring Revenue Growth and Mix
Recurring revenue (consumables, accessories, software, service) grew: company cited 22% year-over-year growth for full-year recurring revenue, representing ~35% of 2025 revenues; Q4 recurring was $5.5M (32% of Q4 revenue), an 11% increase year-over-year.
Operational & Balance Sheet Strength
Company consolidated manufacturing to Danbury, moved to a cost-efficient HQ, reduced operating expenses via headcount and facility actions, ended 2025 with $113M in cash and no debt, and generated ~$0.9M in operating cash in 2025.
Positive 2026 Guidance and Path to Profitability
2026 revenue guidance of $64.5M–$67.5M (15%–20% growth). Handheld product & service revenue expected to grow 13%–17%; AVCAD program contribution guidance $2M–$3M. Company targets mid- to high-50% adjusted gross margins and plans to cut 2025 adjusted EBITDA loss roughly in half in 2026 (to mid-single-digit millions).
Negative Updates
Full-Year Adjusted EBITDA Still Negative
Adjusted EBITDA for full-year 2025 was a loss of $9.6M (although a 39% reduction versus the comparable period cited), indicating progress but ongoing unprofitability on an annual basis.
Large Non-Cash Charges and Reported Net Loss
Full-year net loss from continuing operations was $33.3M vs $53.1M prior year, driven largely by a $47M goodwill impairment and changes in contingent consideration valuation; Q4 net income of $4.4M was materially affected by a $15.2M decrease in non-cash charges.
Supply / Production Constraints and Seasonality Risk
Company noted production/material replenishment limits for Viper after high Q4 demand (>40 units shipped). Seasonality timing may pressure early 2026 quarters (Q1 growth expected in low teens) and constrain near-term upside.
Dependence on Lumpy Federal Contracting & Program Uncertainty
Revenue concentration risk from federal procurement remains; AVCAD program contribution ($2M–$3M expected) depends on awards/RFP timing and remains uncertain. Company consolidated federal contracting partners to one (Mountain Horse) to improve predictability, acknowledging prior lumpiness.
Funding / Grant Uncertainty (DHS)
Homeland Security appropriations were still unresolved at the time of the call. While the company hasn't seen a slowdown in state/local grant-driven purchases, DHS funding uncertainty presents downside timing risk for some demand.
Residual Need for Investment
Management expects to increase selling & marketing (targeted headcount) and make R&D investments for next-gen MX908 commercialization and international expansion, which could temper near-term margin gains despite targeted cost discipline.
Remaining Net Loss and Multi-year Profit Path
Despite Q4 adjusted EBITDA positivity and structural cost improvements, the company still reported a significant full-year net loss and expects 2026 EBITDA to remain negative (mid-single-digit millions), indicating profitability is still a multi-quarter / multi-year objective.
Company Guidance
The company guided 2026 revenue to $64.5–$67.5 million (15%–20% growth vs. $56.2M in 2025), driven by a full‑year impact from Viper and MX908, with handheld product and service revenue expected to grow 13%–17% (management cited a handheld range of ~$59.5M–$61.5M), OEM and funded partnerships of about $3M, and AVCAD program revenue of $2M–$3M; it expects adjusted gross margins in the mid‑ to high‑50% range with at least 100 basis points of expansion, plans to cut the 2025 adjusted EBITDA loss (~$9.6M) roughly in half to the mid‑single‑digit millions in 2026, anticipates Q1 growth in the low teens (≈10%–15%) and Q2 nearer the high end (~20%), and is factoring in operational assumptions such as >40 Viper shipments in Q4 (>$3M revenue) with potential 2–3x Viper volumes in 2026, Explorer momentum (150+ units in 2025; ~40% YoY growth), recurring revenue representing ~35% of 2025 sales, and a strong balance sheet ($113M cash, no debt).908 Devices Financial Statement Overview
Summary
Balance sheet strength (low leverage, sizable equity base) supports solvency, but operating performance remains weak with deeply negative operating/EBITDA margins and negative operating/free cash flow in TTM, raising earnings-quality and funding-risk concerns despite a swing to positive TTM net income.Income Statement
TTM (Trailing-Twelve-Months) revenue was slightly down versus the prior year, while gross margin stayed solid around ~50%, indicating reasonable product economics. However, the core operating picture remains weak with deeply negative operating and EBITDA margins. Net income turned positive in TTM after several years of sizable losses, but profitability looks volatile given the still-large operating loss.46
Neutral
Balance Sheet
The balance sheet is a clear strength: leverage is low with a modest debt-to-equity ratio and a sizable equity base relative to assets, giving the company flexibility. While returns on equity have historically been negative due to losses, TTM turned positive, suggesting improving (though not yet stable) profitability. Overall, solvency risk appears contained.78
Positive
Cash Flow
Cash generation is a key pressure point: operating cash flow and free cash flow are negative in TTM (Trailing-Twelve-Months) and have worsened versus the prior year, implying ongoing cash burn. Cash flow has not consistently tracked profits, highlighted by positive TTM net income alongside negative operating cash flow, which raises questions about earnings quality and near-term funding needs if burn persists.32
Negative
| Breakdown | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 56.20M | 59.63M | 50.23M | 46.85M | 42.21M |
| Gross Profit | 28.42M | 29.93M | 25.32M | 26.02M | 23.23M |
| EBITDA | -21.50M | -43.88M | -40.27M | -31.82M | -20.76M |
| Net Income | 19.49M | -72.21M | -36.40M | -33.56M | -22.17M |
Balance Sheet | |||||
| Total Assets | 190.07M | 159.48M | 202.98M | 242.59M | 260.91M |
| Cash, Cash Equivalents and Short-Term Investments | 112.97M | 69.60M | 145.68M | 188.42M | 224.07M |
| Total Debt | 16.71M | 6.61M | 5.95M | 19.51M | 20.85M |
| Total Liabilities | 46.37M | 44.88M | 37.49M | 51.99M | 46.30M |
| Stockholders Equity | 143.70M | 114.59M | 165.49M | 190.60M | 214.60M |
Cash Flow | |||||
| Free Cash Flow | -24.64M | -30.85M | -27.10M | -22.98M | -29.82M |
| Operating Cash Flow | -23.69M | -30.25M | -25.06M | -20.93M | -29.08M |
| Investing Cash Flow | 50.75M | -46.32M | -26.40M | -15.81M | -737.00K |
| Financing Cash Flow | -697.00K | -376.00K | -15.94M | 1.18M | 94.72M |
908 Devices Technical Analysis
Negative
6.20
Price Trends
6.33
Negative
6.38
Negative
6.69
Negative
Market Momentum
-0.09
Positive
45.86
Neutral
19.14
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For MASS, the sentiment is Negative. The current price of 6.2 is below the 20-day moving average (MA) of 6.52, below the 50-day MA of 6.33, and below the 200-day MA of 6.69, indicating a bearish trend. The MACD of -0.09 indicates Positive momentum. The RSI at 45.86 is Neutral, neither overbought nor oversold. The STOCH value of 19.14 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for MASS.
908 Devices Risk Analysis
908 Devices disclosed 67 risk factors in its most recent earnings report. 908 Devices reported the most risks in the "Finance & Corporate" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
908 Devices Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
58 Neutral | $232.50M | 9.76 | 13.25% | ― | 4.49% | 3.61% | |
52 Neutral | $546.34M | -9.70 | -18.01% | ― | -2.18% | -30.96% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
51 Neutral | $271.09M | -3.33 | -104.17% | ― | 31.94% | 36.59% | |
48 Neutral | $246.45M | -6.74 | 137.18% | ― | 49.52% | 19.34% | |
47 Neutral | $165.14M | ― | -32.46% | ― | 15.19% | -3.32% | |
46 Neutral | $221.56M | -2.53 | -29.28% | ― | -2.69% | -149.18% |
* Healthcare Sector Average
MASS
908 Devices
6.22
1.93
44.99%
SENS
Senseonics Holdings
6.49
-5.45
-45.63%
QTRX
Quanterix
4.72
-2.43
-33.99%
NNOX
Nano-X Imaging
2.60
-3.14
-54.70%
TLSI
TriSalus Life Sciences
4.02
-1.08
-21.18%
CTKB
Cytek Biosciences
4.25
<0.01
0.24%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.